Richland Firm IsoRay Introduces Promising Cancer Treatment Therapy
Posted on: Monday, 25 October 2004, 15:00 CDT
IsoRay:
Prostate Cancer Patient To Receive A New Seed Therapy At The University of Washington In A Worldwide First for Cesium-131 -0- *T FROM: Barry Bartlett, 206-285-0673; 206-335-4694 (cell) RE: Post-Implant Media Briefing, Tuesday, October 26, 11 a.m. University of Washington Medical Center, Seattle Surgery Pavilion, Conference Room (SP1264, first floor) WHAT: A new isotope for low-dose (LDR) seed brachytherapy will be implanted into prostate cancer patient Chuck Moore at 7:30 a.m.-- marking the first brachytherapy seed implant in the world utilizing the radioactive isotope Cesium-131. This new isotope represents the first major advancement in LDR seed brachytherapy in more than 18 years. WHERE: University of Washington Medical Center, Seattle tomorrow morning at 7:30 a.m. (Tuesday, October 26). BRIEFING: At 11:00 a.m., following this outpatient procedure, Dr. Leroy Korb, assistant professor of Radiation Oncology at UW Medical Center (performing the procedure), patient Chuck Moore and IsoRay Medical, Inc. Chairman and CEO Roger Girard will be available for interviews. TELEVISION B-ROLL: Will be delivered in beta SP format at approximately 3:30 p.m. ADDIONAL BACKGROUND: Craig Degginger, Media Relations Coordinator UW Medical Center, 206-616-3192 More information is available on the IsoRay Medical Web site: www.isoray.com. *T
NOTEWORTHY:
-- IsoRay Medical received Food & Drug Administration (FDA) approval to market its Cs131 Seed for the treatment of prostate cancer and other malignancies in March 2003.
-- The Cs131 Seed by IsoRay Medical combines the beneficial characteristics of a short half-life and high energy, giving it significant clinical advantages over Iodine-125 and Palladium-103, the brachytherapy isotopes commonly used in LDR cancer treatment today. When placed inside or near a tumor, Cs131 Seeds deliver radiation directly to cancer cells while reducing or eliminating damage to surrounding tissue.
-- Initial production is occurring through facilities contracted with the Pacific Northwest National Laboratory and the Department of Energy in Richland, Washington. Production will increase in the third quarter of 2005, when IsoRay Medical opens a fully automated manufacturing facility in Richland. Construction of the new IsoRay Medical facility is expected to begin in March 2005, and the company expects to employ 250 people when it is running at full capacity.
-- Low-dose brachytherapy (from the Greek prefix "brachy," meaning "short" or "close") is a convenient and cost-effective cancer treatment that employs the direct placement of radioactive seeds into or near the tumor. The seeds, about the size of an uncooked grain of rice, are injected into the prostate gland and benefit the patient by providing a high radiation dose to the cancer cells while minimizing the amount of radiation to the surrounding healthy tissue and body organs. Brachytherapy seeds containing the radioactive isotope Iodine-125 were first implanted into a cancer patient in 1967.
-- IsoRay Medical intends to first market its seed for prostate cancer patients, although the treatment holds promise for other types of cancer, including breast, brain, liver, head and neck cancers, and other malignant disease.
Safe Harbor Statement
Statements in this news release about IsoRay Medical, Inc.'s future expectations, including: the advantages of our Cs131seed and all other statements in this release, other than historical facts, are forward-looking statements. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, and our ability to enforce our intellectual property rights, among other factors.
Source: Business Wire
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Greenway Medical Technologies' PrimePatient Solution Transforms Physician/Patient Relationship Through Enhanced Communication Channels and Improved Workflows
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Definitive Guide to Cancer: An Integrated Approach to Prevention, Treatment & Healing By Dr. Lise Alschuler
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- USNS Comfort Conducts 55,465 Patient Treatments in First Month
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- Study Results Positive for New Cancer Drug Therapy for Prostate Patients
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds